MetaCap

Aytu BioPharma (AYTU) vs ProMIS Neurosciences (PMN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aytu BioPharma (AYTU) has outperformed ProMIS Neurosciences (PMN) over the past year, gaining 32.3% versus a loss of 69.9%. Over five years, AYTU leads with a -93.2% price change compared with -98.2% for PMN. Aytu BioPharma is the larger company by market cap ($28.9 million vs $28.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AYTU+32.34%PMN-69.90%
+146%+32%-82%
Nov 21, 20251 yearNov 20, 2026
AYTU-93.42%PMN-98.38%
+24%-40%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AYTU versus PMN key metrics
MetricAYTUPMN
Share price$2.66$3.16
Market cap$28.91M$28.43M
1-day change0.00%-1.56%
YTD return+2.31%-53.73%
1-year return+32.34%-69.90%
5-year return-93.21%-98.24%
Forward P/E17.16—
EPS (TTM)$-1.78$-6.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$57.57M—
Revenue growth (YoY)-13.27%—
Net income (latest FY)$-14.25M$-39.72M
Gross margin63.95%—
Operating margin-14.44%—
Net margin-24.76%—
52-week high$3.07$27.40
52-week low$1.75$2.78
Distance from 52-week high-13.36%-88.47%
Analyst consensusstrong_buynone
Avg. price target upside+263.53%+1248.42%
Average volume141.18K164.88K
Shares outstanding10.87M9.00M
Employees7510
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AYTU has outperformed PMN by 102.2 percentage points over the past year.

About Aytu BioPharma

AYTU stock →

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About ProMIS Neurosciences

PMN stock →

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

AYTU vs PMN FAQ

Which is bigger, Aytu BioPharma or ProMIS Neurosciences?

Aytu BioPharma (AYTU) is larger, with a market capitalization of $28.91M compared with $28.43M for ProMIS Neurosciences (PMN).

Which stock has performed better over the past year, AYTU or PMN?

AYTU returned +32.34% over the past 12 months, compared with -69.90% for PMN (price return, excluding dividends). Past performance does not predict future results.

Are Aytu BioPharma and ProMIS Neurosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons